Subscribe To
MRKR / 3 Penny Stocks Under $1 For You List This Week
MRKR News
By Benzinga
February 17, 2022
Why Are Marker Therapeutics Shares Trading Lower On Thursday?
Marker Therapeutics Inc (NASDAQ: MRKR) shares are trading lower after Roth Capital downgrades the company from Buy to Neutral and lowers the price t more_horizontal
By Benzinga
February 17, 2022
Why Are Marker Therapeutics Shares Trading Lower On Thursday?
Marker Therapeutics Inc (NASDAQ: MRKR) shares are trading lower after Roth Capital downgrades the company from Buy to Neutral and lowers the price t more_horizontal
By Benzinga
February 17, 2022
Why Are Marker Therapeutics Shares Trading Lower On Thursday?
Marker Therapeutics Inc (NASDAQ: MRKR) shares are trading lower after Roth Capital downgrades the company from Buy to Neutral and lowers the price t more_horizontal
By PennyStocks
January 20, 2022
3 Penny Stocks Under $1 For You List This Week
Penny stocks to watch today The post 3 Penny Stocks Under $1 For You List This Week appeared first on Penny Stocks to Buy, Picks, News and Information more_horizontal
By PennyStocks
January 20, 2022
3 Penny Stocks Under $1 For You List This Week
Penny stocks to watch today The post 3 Penny Stocks Under $1 For You List This Week appeared first on Penny Stocks to Buy, Picks, News and Information more_horizontal
By PennyStocks
January 20, 2022
3 Penny Stocks Under $1 For You List This Week
Penny stocks to watch today The post 3 Penny Stocks Under $1 For You List This Week appeared first on Penny Stocks to Buy, Picks, News and Information more_horizontal
By Benzinga
January 20, 2022
Marker Therapeutics Stock Gains On FDA Orphan Drug Tag For Second MultiTAA-Cell Therapy For Pancreatic Cancer
The FDA has granted Orphan Drug Designation to Marker Therapeutics Inc's (NASDAQ: MRKR) MT-601, a multi-tumor-associated antigen (MultiTAA)-specif more_horizontal
By Benzinga
January 20, 2022
Marker Therapeutics Stock Gains On FDA Orphan Drug Tag For Second MultiTAA-Cell Therapy For Pancreatic Cancer
The FDA has granted Orphan Drug Designation to Marker Therapeutics Inc's (NASDAQ: MRKR) MT-601, a multi-tumor-associated antigen (MultiTAA)-specif more_horizontal